TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...

In a report released yesterday, Josh Jennings from TD Cowen maintained a Hold rating on Becton Dickinson (BDX – Research Report), with a price ...

Wednesday, analysts at TD Cowen increased their price target on Fiserv (NYSE:FI) shares from $235.00 to $277.00, while retaining a Buy rating on the stock. The stock, currently trading at $229.53, has ...

In a report released today, William Katz from TD Cowen maintained a Hold rating on Artisan Partners (APAM – Research Report), with a price ...

Arthur J. Gallagher & Co. (AJG) stock saw a modest uptick, ending the day at $312.21 which represents a slight increase of $3.21 or 1.04% from the prior close of $309. The stock opened at $309 and ...

OSI Systems, Inc. (NASDAQ: OSIS), today announced that it will present at the TD Cowen 46th Annual Aerospace & Defense Conference on Wednesday, February 12, 2025, at 10:45 AM ET.

The transportation sector will be impacted by Trump's new tariff regime. Parcel consolidators and freight forwarders - like ...

Knight-Swift Transportation Holdings Inc (KNX) stock saw a modest uptick, ending the day at $56.44 which represents a slight increase of $0.71 or 1.27% from the prior close of $55.73. The stock opened ...

Johnson & Johnson (NYSE: JNJ) will present at the 45th Annual TD Cowen Healthcare Conference on Tuesday, March 4th, 2025. Management will participate in a fireside chat at 11:10 a.m. Eastern Time.

Noting that Ambry is a profitable testing laboratory that generates more than $300 million of revenue annually, the investment bank thinks that the deal will enable TEM to start generating positive ...

TD Cowen expressed concerns about valuation. “If Celsius can’t demonstrate a path back to growth, it could end up being valued at a multiple more similar to other ex-growth CPG companies,” the note ...

TD Cowen initiated coverage of KalVista (KALV) with a Buy rating and $30 price target The firm cites sebetralstat’s opportunity as the first oral acute therapy for hereditary angioedema attacks ...